RY764
RY746 is a selective MC4R agonist, with an EC50 of 10 nM. RY764 effectively inhibits food intake and reduces body weight gain in diet-induced obese (DIO) rat models. RY764 can be used for the study of obesity.
For research use only. We do not sell to patients.
- CAS No.: 491845-95-5
- Formula: C34H51FN4O3
- Molecular Weight:582.79
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
MC4R 10 nM (EC50) |
MC3R 70 nM (EC50) |
MC1R 580 nM (EC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
160 μM
Compound: 3 (1R,4S,6R,1'R)
|
Effective concentration (binding affinity) exhibited against human melanocortin receptor 1 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
Effective concentration (binding affinity) exhibited against human melanocortin receptor 1 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
|
[PMID: 15982875] |
| CHO | IC50 |
3 μM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against mouse melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against mouse melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | IC50 |
3 μM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against rat melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against rat melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | IC50 |
7 μM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against dog melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against dog melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | IC50 |
750 μM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against human melanocortin receptor 1 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against human melanocortin receptor 1 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | EC50 |
11 nM
Compound: 3 (1R,4S,6R,1'R)
|
Effective concentration (binding affinity) exhibited against human melanocortin receptor 4 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
Effective concentration (binding affinity) exhibited against human melanocortin receptor 4 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
|
[PMID: 15982875] |
| CHO | EC50 |
11 μM
Compound: 3 (1R,4S,6R,1'R)
|
Effective concentration (binding affinity) exhibited against human melanocortin receptor 4 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
Effective concentration (binding affinity) exhibited against human melanocortin receptor 4 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
|
[PMID: 15982875] |
| CHO | EC50 |
850 nM
Compound: 3 (1R,4S,6R,1'R)
|
Effective concentration (binding affinity) exhibited against human melanocortin receptor 5 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
Effective concentration (binding affinity) exhibited against human melanocortin receptor 5 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
|
[PMID: 15982875] |
| CHO | EC50 |
850 μM
Compound: 3 (1R,4S,6R,1'R)
|
Effective concentration (binding affinity) exhibited against human melanocortin receptor 5 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
Effective concentration (binding affinity) exhibited against human melanocortin receptor 5 by radio labeled ligand assay (Displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells)
|
[PMID: 15982875] |
| CHO | IC50 |
>10000 nM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against human melanocortin receptor 2 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against human melanocortin receptor 2 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | IC50 |
8 nM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against human melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against human melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | IC50 |
8 μM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against human melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against human melanocortin receptor 4 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | IC50 |
942 nM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against human melanocortin receptor 3 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against human melanocortin receptor 3 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | IC50 |
942 μM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against human melanocortin receptor 3 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against human melanocortin receptor 3 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | IC50 |
945 nM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against human melanocortin receptor 5 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against human melanocortin receptor 5 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
| CHO | IC50 |
945 μM
Compound: 3 (1R,4S,6R,1'R)
|
Inhibition concentration (binding affinity) against human melanocortin receptor 5 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
Inhibition concentration (binding affinity) against human melanocortin receptor 5 by displacement of [125I]NDP-alpha-MSH from the human receptors expressed in CHO cells
|
[PMID: 15982875] |
Chemical Information
-
CAS No. 491845-95-5
-
Molecular Weight 582.79
-
Formula C34H51FN4O3
-
SMILES
CC(C)(C)NC(C1(C2CCCCC2)CCN(CC1)C([C@H](NC([C@H]3[C@]4([H])N(C[C@](CC4)([H])C3)C)=O)CC5=CC=C(C=C5)F)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)